spacer
home > pmps > winter 2019 > perfect packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Perfect Packaging

Far too frequently, life sciences brands have to withdraw products from the market at great cost and risk to their reputation. This is usually because errors have slipped through, which could impact patient safety. Why is this still happening, and what is needed to ensure companies get high quality, compliant products onto the market promptly and efficiently? This article explores the challenges and charts a way forward.

In this age of automation, it seems astounding that some fundamental tasks, such as packaging and labelling quality checks, are still handled manually, at least to some degree. This is the case, even among some of the biggest pharmaceutical brands, despite the high regulatory standards designed to protect patients, the reputational risks, and steep costs if errors slip through the net.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marc Chaillou is Regional Sales Director at Schlafender Hase, a company that provides intelligent proofreading software, managing key accounts and collaborating with sales partners in export markets. Before joining the company seven years ago, he worked in business development roles at technology market analysts Gartner and Datamonitor. Marc speaks four languages fluently: French, English, Spanish, and German.
spacer
Marc Chaillou
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PredictImmune announce issuance of new patent in the US in support of commercialisation

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property (IP) relating to methods for predicting autoimmune disease risk. This follows successful grants across the company’s first family of IP in the UK and Europe in October 2018 and Canada in January this year.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement